Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C16H17Cl2N5O2 |
|||
Molecular Weight | 382.24 | CAS No. | 844442-38-2 | |
Solubility (25°C)* | In vitro | DMSO | 10 mg/mL (26.16 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. AT7519 also decrease GSK3β phosphorylation. AT7519 induces apoptosis. Phase 2. | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Targets |
|
|||||||||||
In vitro | AT7519 is an ATP competitive CDK inhibitor with a Ki value of 38 nM for CDK1. AT7519 is inactive against all non-CDK kinases with the exception of GSK3β (IC50 = 89 nM). AT7519 shows potent antiproliferative activity in a variety of human tumor cell lines with IC50 values ranging from 40 nM for MCF-7 to 940 nM for SW620 consistent with the inhibition of CDK1 and CDK2. [1] AT7519 induces dose-dependent cytotoxicity in multiple myeloma (MM) cell lines with IC50 values ranging from 0.5 to 2 μM at 48 hours, with the most sensitive cell lines being MM.1S (0.5 μM) and U266 (0.5 μM) and the most resistant MM.1R (>2 μM). It does not induce cytotoxicity in peripheral blood mononuclear cells (PBMNC). AT7519 partially overcomes the proliferative advantage conferred by IL6 and IGF-1 as well as the protective effect of bone marrow stromal cells (BMSCs). AT7519 induces rapid dephosphorylation of RNA pol II CTD at serine 2 and serine 5 sites, and leads to the inhibition of transcription, partially contributing to AT7519 induced cytotoxicity of MM cells. AT7519 induces activation of GSK-3β by down-regulating GSK-3β phosphorylation, which also contributes to AT7519 induced apoptosis independent of the inhibition of transcription. [2] | |||||||||||
In vivo | A twice daily dosing of AT7519 (9.1 mg/kg) causes tumor regression of both early-stage and advanced-stage s.c. tumors in the HCT116 and HT29 colon cancer xenograft models. [1] AT7519 treatment (15 mg/kg) inhibits tumor growth and prolongs the median overall survival of mice in the human MM xenograft mouse model in association with increased caspase 3 activation. [2] |
Kinase Assay:[1] |
|
---|---|
Cell Assay:[2] |
|
Animal Study:[2] |
|
|
Data from [Data independently produced by AIDS, 2014, 28(15), 2213-22]
Data from [Data independently produced by PLoS One, 2011, 6(9), e25683]
, , Dr. Srinivas Narasipura of Rush University Medical Center
Identification of Selective ATP-Competitive CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function [ Res Sq, 2023, rs.3.rs-3182731] | PubMed: 37609279 |
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia [ Cancer Cell, 2022, S1535-6108(22)00312-9] | PubMed: 35868306 |
Non-catalytic allostery in α-TAT1 by a phospho-switch drives dynamic microtubule acetylation [ J Cell Biol, 2022, 221-11e202202100] | PubMed: 36222836 |
Interleukin-15 enhanced the survival of human γδT cells by regulating the expression of Mcl-1 in neuroblastoma [ Cell Death Discov, 2022, 8(1):139] | PubMed: 35351861 |
Modulation of Primary Cilia by Alvocidib Inhibition of CILK1 [ Int J Mol Sci, 2022, 23(15)8121] | PubMed: 35897693 |
O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition [ Glycobiology, 2022, cwac038] | PubMed: 35708495 |
Cdk2 suppresses IL-23 expression and the onset of severe acute pancreatitis [ Immun Inflamm Dis, 2022, 10(6):e631] | PubMed: 35634959 |
Biochemical and structural insights into SARS-CoV-2 polyprotein processing by Mpro [ Sci Adv, 2022, 8(49):eadd2191] | PubMed: 36490335 |
KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM) [ NAR Cancer, 2022, 4(3):zcac024] | PubMed: 35910692 |
Phosphorylation of a Human Microprotein Promotes Dissociation of Biomolecular Condensates [ J Am Chem Soc, 2021, 10.1021/jacs.1c05386] | PubMed: 34346674 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.